New study reveals advantage of Spencer’s formulations
Research by Quebec University reveals the advantages of Spencer Pharmaceutical’s oral formulations
Research by the University of Quebec at Montreal (UQAM) has revealed the advantages of Spencer Pharmaceutical’s oral formulae, the company says.
US based Spencer Pharmaceutical says its technology provides a "pain free" advantage and was found to present a noticeable versatility in terms of size and characteristics of the therapeutic molecule to be delivered.
'It was found that our excipient was able to formulate small-size molecules either polar (hydrophilic such as metformin or ibuprofen) or non polar (as acetaminophen) as well as medium or large-size molecules such as bioactive peptides (ex. Nisin), proteins or even microorganisms (probiotics), essentially applying to many popular over-the-counter drugs and prescribed as well,' said Dr Max Arella, ceo of the company.
However many of the delivery technologies for therapeutic peptides or proteins failed to overcome three major obstacles: i) Denaturation of the peptide or of the protein or bacterium by gastric acid and even by pepsin protease in the stomach environment; ii) Degradation of the peptide or protein or bacterium by the attack of proteolytic enzymes in intestine; iii) Poor or limited absorption of the peptide or protein into the bloodstream (if not directed to the colon).
Spencer says its matrix is versatile and affords a gastro-protection against acidity and proteolysis, particularly in the case of sensitive bioactive agents (peptides, proteins, bacteria) contributing thus to their stability during the gastric and intestinal transit.
In addition, it possesses the muco-adhesive properties that can prevent proteolysis and enhance their intestinal mucosal retention or uptake to the bloodstream in an active form.
'By overcoming these obstacles, our technology represents a major advancement in orally peptide or protein delivery, making easier and less painful their administration, increasing the patient compliance. Due to its versatility, we believe that our technology will markedly reduce the overall costs of manufacturing effective drugs,' the company says.
